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AbstrAct
Studyobjectives Daytime sleep has been associated 
with increased risk of cardiovascular disease and heart 
failure (HF), but the mechanisms remain unclear. We have 
investigated the association between daytime and night-
time sleep patterns and cardiovascular risk markers in 
older adults including cardiac markers and subclinical 
markers of atherosclerosis (arterial stiffness and carotid 
intima-media thickness (CIMT)).
Methods Cross-sectional study of 1722 surviving men 
aged 71–92 examined in 2010–2012 across 24 British 
towns from a prospective study initiated in 1978–1980. 
Participants completed a questionnaire and were invited 
for a physical examination. Men with a history of heart 
attack or HF (n=251) were excluded from the analysis.
Results Self-reported daytime sleep duration was 
associated with higher fasting glucose and insulin levels 
(p=0.02 and p=0.01, respectively) even after adjustment 
for age, body mass index, physical activity and social 
class. Compared with those with no daytime sleep, men 
with daytime sleep >1 hour, defined as excessive daytime 
sleepiness (EDS), had a higher risk of raised N-terminal 
pro-brain natriuretic peptide of ≥400 pg/mL, the diagnostic 
threshold for HF (OR (95% CI)=1.88 (1.15 to 3.1)), higher 
mean troponin, reduced lung function (forced expiratory 
volume in 1 s) and elevated von Willebrand factor, a 
marker of endothelial dysfunction. However, EDS was 
unrelated to CIMT and arterial stiffness. By contrast, night-
time sleep was only associated with HbA1c (short or long 
sleep) and arterial stiffness (short sleep).
Conclusions Daytime sleep duration of >1 hour may be 
an early indicator of HF.
IntroductIon
Sleep disturbance is a common complaint, 
especially among older adults.1 It is increas-
ingly recognised that there is a U-shaped 
association between sleep duration and risk 
of cardiovascular disease (CVD) and meta-
bolic disturbances, that is both short and 
long sleep durations are associated with an 
increased risk.2–4 More recently, studies have 
shown excessive daytime sleepiness (EDS), 
one of the more common sleep disturbances 
reported in the older population, to be asso-
ciated with increased risks of CVD,5 6 heart 
failure (HF)6 7 and all-cause mortality.8–10
The mechanism of the association between 
EDS and CVD risk remains unclear. While 
some studies have looked at the associ-
ation between EDS and metabolic risk 
markers,11 12 few have examined mechanisms 
by which EDS may influence CVD and in 
particular incident HF.6 In particular, the 
association between EDS and markers of arte-
rial disease and surrogate markers of cardiac 
function, including N-terminal pro-brain 
natriuretic peptide (NT-pro-BNP), a marker 
of ventricular stress, and cardiac troponin 
T (cTnT), a marker of myocardial injury, 
have been less studied. Subclinical arterial 
disease markers are increasingly being used 
as early predictors for atherosclerosis and 
CVD. A number of non-invasive assessments 
have been developed, including measures of 
atherosclerosis such as carotid intima-media 
thickness (CIMT) and indirect measures of 
arterial stiffness including carotid disten-
sibility and pulse wave velocity (PWV). 
Although a number of studies have exam-
ined the association between night-time sleep 
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Research
Strengths and limitations of this study
 ► To the best of our knowledge, this is the first study 
to look at the association between excessive 
daytime sleepiness, cardiac markers and vascular 
parameters.
 ► Owing to a lack of data, we do not know if the 
associations seen are true for women, middle-aged 
populations and ethnic minorities.
 ► As we do not have polysomnography data, we were 
unable to fully exclude obstructive sleep apnoea as 
a contributing factor to our findings.
 ► Our results are based on a cross-sectional analysis 
and therefore causality cannot be established.
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duration and arterial stiffness,13–17 studies on the associa-
tion between EDS and vascular risk markers are limited.5 
We have therefore examined the association between 
daytime sleep as well as night-time sleep with vascular risk 
factors including metabolic risk factors, inflammatory 
and endothelial markers, cardiac markers and measures 
of subclinical arterial disease (including arterial stiffness 
and CIMT).
Methods
The British Regional Heart Study is a prospective study 
that recruited a socioeconomically and geographically 
representative cohort of 7735 men from 24 British towns 
between 1978 and 1980. The present investigation is 
based on a reassessment in 2010–2012, when all surviving 
men (n=3137), aged between 71 and 92 years, were sent a 
postal questionnaire and invited for a 30th year re-exam-
ination. A total of 2137 (68%) men completed the postal 
questionnaire, and 1722 (55%) men attended the re-ex-
amination.18 Blood samples were collected after fasting for 
a minimum of 6 hours and were stored at −70°C. Ethical 
approval for data collection was obtained from the rele-
vant research ethics committee. The men were asked if a 
doctor had ever told them they had a heart attack or HF, 
and these men were excluded from the analysis (n=251). 
Of the men with no history of heart attack or HF, 1471 
men had physical, blood and ultrasound measurements 
carried out. This present study is a cross-sectional analysis 
of the data from the 2010–2012 questionnaires and re-ex-
amination.
cVd risk factors
Physical examination included blood pressure (BP), lung 
function as well as height and weight, from which body 
mass index (BMI) was calculated.19 Height standardised 
forced expiratory volume in 1 s (FEV1) was measured 
using the Vitalograph Compact II. Details of measure-
ment and classification for smoking status and physical 
activity in this cohort have been previously described.20 
Details of the men’s medication history, including use of 
antihypertensive, hypnotic and anxiolytic medications, 
were recorded at the examination, and participants 
were also asked to report symptoms of breathlessness. 
Measurements of metabolic, inflammatory and endo-
thelial markers were taken as described previously.19 21 22 
NT-pro-BNP and cTnT were measured using the Elecsys 
2010 electrochemiluminescence method (Roche Diag-
nostics, Burgess Hill, UK). The lowest detectable value 
of cTnT was 5 and for anyone with a recorded reading 
of <5, we used half of the lowest detectable value (ie, 
2.5). NT-pro-BNP ≥400 pg/mL was defined as high, as 
per current guidelines issued by the National Institute of 
Clinical Excellence for the diagnosis of HF.23 Prevalent 
diabetes included men with doctor-diagnosed diabetes 
and men with fasting blood glucose ≥7 mmol/L. A total 
of 1402 men had at least one blood measurement (69 
missing). Chronic kidney disease (CKD) was defined as 
estimated glomerular filtration rate of less than 60ml/
min/1.73m2 using the CKD Epidemiology Collaboration 
creatinine equation.24
sleep parameters 
Reported duration of night sleep was based on response 
to: ‘On average, how many hours of sleep do you have each 
night?’ Duration of day sleep was based on response to 
‘On average, how much sleep (if any) do you have during 
the daytime?’ If a response was entered for the night sleep 
question but no response was indicated for the day sleep 
question, the answer was set to 0. A total of 1436 men 
completed the questions on night-time and daytime sleep 
duration (35 missing). Night-time sleep was categorised 
into three groups: <6, 6–8.9 and ≥9 hours. Daytime sleep 
was categorised into four groups: 0 hours, <1 hour, 1 hour 
and >1 hour. Those sleeping >1 hour during the daytime 
were defined as having EDS.
non-invasive markers of arterial disease 
Measurements were measured by two vascular techni-
cians in series. Left and right carotid arteries were images 
using a Z.One Ultra ultrasound system (Zonare Medical 
Systems, Mountain View, California, USA) with a 5 mHz 
to 10 mHz linear probe. A cross-sectional sweep from 
the base of the common carotid artery to the jaw bone 
and longitudinal images of the common carotid artery 
approximately 1 cm proximal to the carotid bifurcation 
were recorded. Peak systolic and end-diastolic common 
carotid artery diameter and CIMT, the distance between 
the leading edge of the intima and the media-adventitia 
interface, were measured using Carotid Analyser software 
(Medical Imaging Applications, Iowa City, Iowa, USA). 
From the longitudinal images, a region of interest 
(5–10 mm) was selected in a plaque free area, at least 1 cm 
from the bifurcation.
CIMT was measured from three end-diastolic images 
on each side, and a mean of these measures was calcu-
lated. Maximum and minimum carotid artery diameter 
was assessed from three consecutive waveforms and 
mean distension was calculated as: maximum diameter 
− minimum diameter. The distensibility coefficient was 
then calculated as described by Dijk et al: distensibility 
coefficient = [(2 × mean distension/baseline diameter)/
mean pulse pressure (kPa)]*1000.25 Carotid to femoral 
PWV was assessed using a Vicorder (Skidmore Medical, 
Bristol, UK), with participants in a semisupine position 
with their torso at approximately 30°. A 2×9 cm cuff was 
positioned around the neck with the bladder over the 
right carotid pulse, and a Hokanson SC10 cuff around 
the middle of the right thigh. Path length was measured 
from the sternal notch to the centre of the thigh cuff. 
The cuffs were simultaneously inflated and traces with 
a minimum of three good quality waveforms recorded. 
Two PWV measurements, within ≤0.5 m/s of each other, 
were accepted and averaged. A total of 1464 men had at 
least one non-invasive vascular measurement carried out 
(seven missing).
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statistical analysis
Distributions of HbA1c, glucose, insulin, C reactive 
protein (CRP), interleukin (IL)-6, NT-pro-BNP and cTnT 
were highly skewed, and log transformation was used. 
Comparisons of baseline characteristics between the 
sleep groups were carried out using the χ2 test for cate-
gorical variables and analysis of variance for continuous 
variables. Logistic regression models were used to assess 
the differences in outcomes between categorical groups. 
In multivariate analyses, age, BMI, physical activity and 
social class were fitted as continuous variables, while prev-
alent diabetes and use of antihypertensive medications 
was defined as categorical variables. The base groups for 
the statistical analysis were the group sleeping 6–8.9 hours 
in the night-time sleep group. A threshold effect was seen 
in those sleeping >1 hour in the daytime, and therefore we 
compared those sleeping >1 hour with those sleeping ≤1. 
We also carried out statistical analysis of the trend in the 
daytime sleep group. All analyses were performed using 
SAS V.9.3.
results
The average duration of night-time sleep in the men who 
responded was 6.8 hours (±1.4 hours). Fifteen per cent of 
the men reported night-time sleep duration of less than 
6 hours, while 7% reported sleeping ≥9 hours during the 
night. Forty-seven per cent of men reported no daytime 
sleep, while 9% reported EDS. Night-time sleep duration 
was significantly associated with EDS (p=0.02; correlation 
coefficient r=−0.063), with a smaller proportion of those 
sleeping ≥9 hours reporting EDS. Daytime sleep duration 
was significantly associated with night-time sleep of less 
than 6 hours (p=0.02).
Baseline characteristics
Table 1 describes the baseline characteristics of the study 
population according to night-time and daytime sleep 
patterns. A U-shaped relationship was seen between 
night-time sleep and CVD risk factors. Both short and 
long night-time sleep were associated with increased 
age, increased prevalence of physical inactivity, manual 
workers and breathlessness compared with those with 
6–8.9 hours sleep. There was a significant association 
between night-time sleep and use of hypnotic or anxio-
lytic medications. Daytime sleep is strongly associated with 
older age and with many adverse characteristics including 
physical inactivity, obesity, prevalent diabetes, breathless-
ness, use of antihypertensive medication, depression and 
CKD. The prevalence of these adverse factors tended 
to increase with increasing duration of daytime sleep. 
Daytime sleep was not associated with use of hypnotic or 
anxiolytic medications.
night-time sleep and and cardiovascular risk markers
There was a U-shaped association between night-time 
sleep and metabolic risk factors including HbA1c 
and glucose (table 2). The association between night-
time sleep and HbA1c remained significant following 
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Table 2 Night-time sleep duration versus metabolic risk factors, inflammatory and endothelial markers, lung function and 
cardiac markers
Night sleep (hours)
p<6(n=213¶) 6–8.9(n=1126¶) ≥9(n=97¶)
Metabolic risk factors (mean (95% CI))
SBP (mm Hg) † 146.04 (143.52 to 148.56) 147.31 (146.21 to 148.4) 150.73 (146.99 to 154.47) 0.12
DBP (mm Hg) † 76.59 (75.07 to 78.11) 77.46 (76.8 to 78.12) 77.25 (74.99 to 79.5) 0.59
HDL-C (mmol/L) † 1.47 (1.41 to 1.53) 1.48 (1.45 to 1.5) 1.37 (1.28 to 1.46) 0.07
Triglycerides (mmol/L) † 1.3 (1.21 to 1.39) 1.28 (1.25 to 1.32) 1.39 (1.26 to 1.52) 0.31
HbA1c§ (%) † 5.93 (5.85 to 6.02) 5.75 (5.72 to 5.79) 5.88 (5.76 to 6) 0.0001*
‡ 5.9 (5.82 to 5.98) 5.76 (5.73 to 5.79) 5.86 (5.74 to 5.97) 0.003*
Glucose§ (mmol/L) † 5.78 (5.62 to 5.94) 5.55 (5.48 to 5.61) 5.72 (5.49 to 5.95) 0.02*
‡ 5.74 (5.58 to 5.9) 5.56 (5.49 to 5.62) 5.68 (5.45 to 5.91) 0.08
Insulin§ (mU/L) † 8.26 (7.54 to 9.04) 7.92 (7.62 to 8.24) 7.82 (6.84 to 8.94) 0.69
Inflammatory and endothelial markers (mean (95% CI))
CRP§ (mg/L) † 1.51 (1.28 to 1.78) 1.34 (1.25 to 1.44) 1.46 (1.15 to 1.87) 0.37
IL-6§ (pg/mL) † 3.03 (2.74 to 3.35) 2.98 (2.86 to 3.11) 3.72 (3.21 to 4.3) 0.02*
‡ 2.94 (2.67 to 3.25) 3 (2.87 to 3.13) 3.61 (3.12 to 4.18) 0.05
vWF (IU/dL) † 140.97 (130.97 to 150.97) 133.27 (128.91 to 137.63) 119.04 (104.2 to 133.89) 0.06
Lung function (mean (95% CI))
FEV1 (L) † 2.43 (2.35 to 2.5) 2.46 (2.42 to 2.49) 2.44 (2.32 to 2.55) 0.76
Cardiac markers (mean (95% CI))
NT-pro-BNP§ (pg/mL) † 121.67 (101.33 to 146.1) 126.45 (116.87 to 136.81) 134.61 (102.8 to 176.25) 0.83
cTnT§ (pg/mL) † 11.25 (10.29 to 12.3) 10.82 (10.41 to 11.24) 10.14 (8.89 to 11.57) 0.44
†Adjusted for age.
‡Adjusted for age, BMI, social class and physical activity.
§Geometeric mean.
¶Maximum n in group, varies slightly with missing covariate data.
BMI, body mass index; CRP, C reactive protein; cTnT, cardiac troponin T; DBP, diastolic blood pressure; FEV1, forced expiratory volume in 1 
s; HbA1c, glycated haemoglobin; HDL-C, high density lipoprotein cholesterol; IL-6, interleukin 6; NT-pro-BNP, N-terminal pro-brain natriuretic 
peptide; SBP, systolic blood pressure; vWF, von Willebrand factor.
adjustment for daytime sleep (p=0.04). In age-adjusted 
analysis, night-time sleep was significantly associated with 
IL-6, a marker of inflammation, but this association was 
attenuated following adjustment for BMI, social class and 
physical activity (p=0.05). No significant association was 
seen between night-time sleep and von Willebrand factor 
(vWF), a marker of endothelial function, FEV1 (lung 
function) or cardiac markers (NT-pro-BNP and cTnT).
daytime sleep and cardiovascular risk markers
In age-adjusted analysis, metabolic risk factors including 
high density lipoprotein cholesterol, triglycerides, HbA1c 
and insulin tended to increase with increasing hours of 
daytime sleep (table 3). No association was seen with BP. 
The increasing trend was attenuated after adjustment 
for age, BMI, social class and physical activity. However, 
compared with those who slept <1 hour, those with EDS 
(>1 hour) showed significantly higher mean levels of 
HbA1c, glucose and insulin (table 3). Mean levels of 
glucose and insulin remained significantly higher in 
those with EDS (p=0.03 and 0.01, respectively) even after 
further adjustment for prevalent diabetes and night-time 
sleep.
CRP increased with increasing daytime sleep duration, 
even after full adjustment (p trend=0.04). Lung function 
decreased with increasing daytime sleep duration with 
levels markedly reduced in those with EDS compared with 
those reporting <1 hdaytime sleep (p<0.0001). Only EDS 
was associated with significantly higher mean vWF levels 
(p=0.03). When we examined the odds of having high 
vWF (top quintile) and low FEV1 (lowest quintile), those 
with EDS were 1.8 times more likely to have a high vWF 
(OR (95% CI)=1.82 (1.17 to 2.83)) and 2.4 times more 
likely to have a low FEV1 (OR (95% CI)=2.4 (1.53, 3.74)) 
compared with those who reported no daytime sleep.
Mean levels of NT-pro-BNP and cTnT (cardiac markers) 
were significantly higher only in those with EDS following 
full adjustment (p=0.02 and p=0.03 respectively). This 
association remained significant even after adjustment 
for CKD. Men with EDS were more likely to have high 
(top quintile) mean NT-pro-BNP (OR (95% CI)=1.69 
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(1.06 to 2.7)) and cTnT (OR (95% CI)=1.75 (1.09 to 
2.8)) compared with those who reported no daytime 
sleep. However, this was attenuated following adjustment 
for prevalent diabetes, use of antihypertensive medica-
tion and depression (OR (95% CI)=1.59 (0.99 to 2.55)) 
and (OR (95% CI)=1.62 (1.00 to 2.62)), respectively, 
although it remained significant for cTnT. We further 
looked at men with an NT-pro-BNP of ≥400 pg/mL, the 
diagnostic threshold for HF. Men who reported EDS 
had a higher odds of having an NT-pro-BNP of ≥400 pg/
mL (OR (95% CI)=1.88 (1.15 to 3.1)). This association 
remained following adjustment for prevalent diabetes, 
CKD, use of antihypertensive medication and depression 
(OR (95% CI)=1.72 (1.03 to 2.87)). Exclusion of men 
using anxiolytic and hypnotic medications did not signifi-
cantly alter this (OR (95% CI)=1.76 (1.05 to 2.95)).
sleep patterns and non-invasive markers of arterial disease
Table 4 shows the associations between sleeping patterns 
and non-invasive vascular measurements. There was a 
significant association between those sleeping <6 hours 
and mean PWV and distensibility when compared 
with those sleeping 6–8.9 h in the fully adjusted model 
(p=0.04 and p=0.03, respectively). Men who slept <6 hours 
during the night-time were 1.6 times more likely to have 
a low (lowest quintile) mean distensibility compared with 
those who slept 6–8.9 hours in the fully adjusted model 
(OR (95% CI)=1.56 (1.09 to 2.23)). There was no signif-
icant association between daytime sleep and markers 
of arterial stiffness. There was no association between 
sleeping patterns and CIMT in the study population.
dIscussIon
We have confirmed previous reports of an association 
between night-time sleep duration4 and daytime sleep 
duration11 12 with metabolic risk factors. Our findings 
extend previous studies by investigating the association 
between EDS and a wide range of cardiac markers and 
vascular measures not previously examined. Our study 
has shown that in a representative sample of British men 
aged 71–92 years with no prior history of heart attack or 
HF, those who sleep more than 1 h during the day have 
a number of adverse characteristics including higher 
mean levels of cardiac markers, metabolic risk factors, 
inflammatory and endothelial markers and reduced lung 
function. These findings may point to pathways for the 
association observed between EDS and CVD and all-cause 
mortality.8
eds and metabolic and cardiac risk markers
EDS, defined in our study as daytime sleep of >1 h, is 
associated with many adverse characteristics such as 
obesity, physical inactivity, diabetes, breathlessness, use 
of antihypertensive therapy and with an adverse pattern 
of metabolic risk factors including HbA1c, glucose and 
insulin. Our results confirm previous cross-sectional 
analyses that have shown EDS to be associated with 
the metabolic syndrome and longer habitual napping 
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duration to be associated with an increased risk of 
impaired fasting glucose and diabetes mellitus.11 12 There 
was a significant linear relationship between increasing 
daytime sleep and mean CRP levels, with those reporting 
EDS having higher levels of mean CRP. This confirms 
results from a previous study that showed self-reported 
daytime napping is associated with higher levels of CRP 
in older British adults.26 The association seen between 
daytime sleep and these markers of inflammation may 
provide an explanation for the excess all-cause mortality 
observed in those with daytime napping or EDS.8 9 While 
both of these studies have adjusted for diabetes, neither 
has adjusted for inflammation.
We found a significant association between EDS and 
high levels of NT-pro-BNP and cTnT, both of which 
are biomarkers of HF.27 28 NT-pro-BNP is produced in 
response to cardiac wall stress and is a strong predictor of 
HF.22 Troponin T is a plasma marker of myocyte necrosis, 
which has been positively associated with incident CVD, 
HF and all-cause mortality.29 Most notably men who 
reported EDS had a higher odds of having NT-pro-BNP 
of ≥400 pg/mL (the diagnostic threshold for HF). As far 
as we are aware, this is the first study to look at the associ-
ation between EDS and these cardiac markers.
A strong association was also seen between EDS and 
elevated vWF (marker of endothelial dysfunction) and 
low FEV1, markers associated with HF. These findings 
suggest that EDS may be an early indicator of HF. This 
supports a recent report from our study when the men 
were aged 63–82 years which showed EDS to be associ-
ated with the risk of developing overt HF during 9-year 
follow-up.7 In that analyses cardiac markers and lung 
function were not available.
The association between EDS and HF may be explained 
by underlying respiratory illness such as obstructive sleep 
apnoea (OSA). Indeed within our cohort, EDS was 
significantly associated with obesity, self-reported breath-
lessness and reduced lung function. EDS may be a result 
of disturbed night-time sleep and difficulty falling asleep, 
both of which have been associated with HF.30 31 However, 
the associations we observed with cardiac markers and 
lung function were not seen in men with a short or long 
duration of night-time sleep and further analyses showed 
no association between these markers and those reporting 
difficulty falling asleep.
non-invasive markers of arterial disease
In contrast to night-time sleep, we did not observe 
any significant association between daytime sleep and 
markers of arterial stiffness. Short night-time sleep but 
not long night-time sleep was associated with arterial stiff-
ness (PWV and carotid distensibility), when compared 
with those sleeping 6–8.9 hours. There was no association 
between sleeping patterns and CIMT in the study popula-
tion. This is in contrast to previous studies that have shown 
an association between short night-time sleep17 and EDS5 
with CIMT. The differences observed may be due to use 
of brachial-ankle PWV,13 15 rather than carotid-femoral 
PWV, different classification of long night-time sleep13 14 
and a younger study population.15
strengths and limitations
The strengths of our study include the fact that it is a study 
of older men, a group who are at high risk of vascular 
disease and the wide range of vascular parameters that we 
have looked into. Limitations of our study include the lack 
of representation of women, middle-aged populations and 
ethnic minority groups, which limits generalisability. Our 
data is based on self-reported sleeping patterns at a single 
time point, and it is possible that night-time and daytime 
sleep duration have been misclassified. Our analysis of 
night-time sleep relies on average duration of night-time 
sleep, and we do not have measures of interruption or 
total time spent in bed. As we do not have polysomnog-
raphy data, we were unable to fully exclude OSA as a 
contributing factor to our findings. Data regarding occu-
pation were not available, and we were unable to assess if 
previous shift work, which has been reported to be associ-
ated with cardiovascular and metabolic diseases, is related 
to the adverse cardiovascular profile we noted in those 
with EDS. We appreciate that our results are based on a 
cross-sectional analysis, and therefore causality cannot be 
established and the direction of the effect is unknown. It 
is also possible that there is an element of survival bias in 
our data; it may be that men who attended the re-exam-
ination were healthier, and this may account for the null 
associations seen.
conclusions
EDS, defined as daytime sleep of more than 1 hour, is 
associated with an adverse cardiovascular profile and may 
be an early indicator of HF. Clinically, this is important in 
the assessment of older patients who seek medical advice 
for EDS, in whom indicators of HF should be sought and 
further investigations carried out if necessary.
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